Welcome to the latest edition of “Last week in Weed,” catching you up on the latest breaking news and industry developments in the world of cannabis.
Here’s what you may have missed over the last week:
Olympics Spotlight
The Olympic conversation intersected with cannabis policy this week as attention returned to anti-doping rules that continue to prohibit THC during competition. Under World Anti-Doping Agency standards, cannabis remains banned in-competition regardless of local legalization, creating a persistent tension between evolving social norms and elite sport governance.
The broader sports ecosystem is also exploring alternative models. The planned 2026 Enhanced Games, a controversial multi-sport event allowing certain substances, has drawn participation from former Olympians and renewed debate around athlete autonomy, drug policy, and commercialization. While not explicitly cannabis-focused, the event underscores shifting attitudes toward pharmacological enhancement and athlete health narratives that increasingly overlap with cannabinoid research and recovery products.
Federal Infighting and Hemp Shockwaves
Industry attention shifted to Washington after fresh analysis warned that policy conflict around intoxicating hemp cannabinoids could spark a de facto prohibition environment. Congressional moves targeting hemp-derived intoxicants have forced operators to rethink product strategies while lobbying for clearer regulatory definitions.
Compounding uncertainty, the FDA missed a congressionally mandated deadline to publish guidance on cannabinoid classifications and packaging definitions, leaving manufacturers without clarity on compliance thresholds. The delay adds to a regulatory vacuum that is already reshaping formulation, labeling, and interstate commerce strategies across hemp and cannabis markets.
Virginia’s Retail Market Edges Forward
Virginia advanced legislation that could finally launch a regulated adult-use retail system, marking a significant pivot five years after possession was legalized. Proposed frameworks include a 12.9% state tax with optional local surcharges and oversight by the Cannabis Control Authority, positioning the state as one of the most consequential near-term expansion markets.
The bills also highlight unresolved questions around consumption spaces and regulatory structure, with lawmakers ordering studies on social use venues while debating potential agency consolidation with the state alcohol authority. If implemented, retail sales could begin in 2026 or early 2027, accelerating regional competition along the East Coast.
New York Revenue Boom Meets Market Friction
New York reported a sharp rise in cannabis tax revenue, projecting $24 million for fiscal 2026 with further growth expected as licensed storefronts continue opening at a steady pace. Officials attribute gains to rapid retail expansion, with hundreds of shops now operating statewide.
Yet operators caution that revenue growth still lags market potential due to price compression and persistent illicit competition. Industry advocates are pressing for stronger enforcement against unlicensed sellers, arguing that normalization of the legal market depends on improved retail parity and regulatory consistency.
Policy Reform and Rescheduling Reality Check
Federal rescheduling momentum continues to dominate strategic planning across the sector. Analysts warn that while potential tax relief and research access represent clear upside, operators may be underestimating the compliance burdens and competitive pressures that accompany pharmaceutical pathways and federal oversight.
Parallel legislative activity underscores the complexity of reform. State tax adjustments, synthetic cannabinoid crackdowns, and a bipartisan federal HEMP Act illustrate how reform is unfolding as a patchwork of expansion and restriction rather than a unified liberalization trajectory.
Market Growth Signals Despite Regulatory Headwinds
Investor sentiment received a modest boost from forecasts showing the cannabis-infused products market expanding from roughly $33.6 billion in 2025 to more than $41 billion in 2026. The growth projection reflects sustained consumer demand for beverages, edibles, and wellness formulations despite ongoing regulatory volatility.
At the state level, policy adjustments in California and New York continued reshaping retail dynamics. Measures addressing product recalls, zoning protections for dispensaries, and new low-dose beverage licensing categories signal a shift toward market maturation and product segmentation strategies.
